文献速递造血干细胞移植与细胞治疗白血病

ABO血型不合在急性髓系白血病错配无关供者异基因造血细胞移植中的影响:EBMT急性白血病工作组报告

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
PubMed 文献 · Am J Hematol · 2017-06-09

该研究基于EBMT注册组2005至2014年间1013例接受HLA错配无关供者移植的急性髓系白血病患者,比较ABO相合与不合组的移植结局。结果显示两组植入率、复发率、非复发死亡率、3年生存率和无白血病生存率均无显著差异;主要ABO不合组II-IV级急性移植物抗宿主病发生率略低(HR 0.7,95%CI 0.5-1,P=0.049)。作者认为ABO不合在错配无关供者移植中可能无显著临床影响。

要点

  • ABO相合与不合组植入率、复发率、非复发死亡率和3年生存率均无显著差异。
  • 主要ABO不合组II-IV级急性GVHD发生率略低(HR 0.7,95%CI 0.5-1,P=0.049)。
  • 作者认为ABO不合在错配无关供者移植中可能无显著临床影响。

核心结论

  • ABO血型不合在HLA错配无关供者移植治疗急性髓系白血病中可能无显著临床影响。

研究设计与样本

  • 回顾性分析EBMT急性白血病工作组注册组2005至2014年间1013例接受HLA错配无关供者异基因造血细胞移植的急性髓系白血病患者。

主要发现

  • ABO相合组与不合组植入率相当。
  • 复发率:ABO相合组34%(95%CI 28-39) vs ABO不合组36%(95%CI 32-40),P=0.32。
  • 非复发死亡率:ABO相合组28%(95%CI 23-33) vs ABO不合组25%(95%CI 21-29),P=0.2。
  • 3年生存率:ABO相合组40% vs ABO不合组43%,P=0.35。
  • 无白血病生存率:ABO相合组37%(95%CI 32-43) vs ABO不合组38%(95%CI 33-42),P=0.87。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABO incompatibility is commonly observed in stem cell transplantation and its impact in this setting has been extensively investigated. HLA-mismatched unrelated donors (MMURD) are often used as an alternative stem cell source but are associated with increased transplant related complications. Whether ABO incompatibility affects outcome in MMURD transplantation for acute myeloid leukemia (AML) patients is unknown. We evaluated 1,013 AML patients who underwent MMURD transplantation between 2005 and 2014. Engraftment rates were comparable between ABO matched and mismatched patients, as were relapse incidence [34%; 95% confidence interval (CI), 28-39; for ABO matched vs. 36%; 95% CI, 32-40; for ABO mismatched; P = .32], and nonrelapse mortality (28%; 95% CI, 23-33; for ABO matched vs. 25%; 95% CI, 21-29; for ABO mismatched; P = .2). Three year survival was 40% for ABO matched and 43% for ABO mismatched patients (P = .35), Leukemia free survival rates were also comparable between groups (37%; 95% CI, 32-43; for ABO matched vs. 38%; 95% CI, 33-42; for ABO mismatched; P = .87). Incidence of grade II-IV acute graft versus host disease was marginally lower in patients with major ABO mismatching (Hazard ratio of 0.7, 95% CI, 0.5-1; P = .049]. ABO incompatibility probably has no significant clinical implications in MMURD transplantation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Canaani J, Savani BN, Labopin M, et al. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. Am J Hematol. 2017. PMID: 28439910. doi:10.1002/ajh.24771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。